Furthermore, in a phase III trial (n = 133, NCT02893332) evaluating the efficacy of first-generation epidermal growth factor receptor (EGFR) TKI with or without radiation therapy in synchronous oligometastatic EGFR-mutated NSCLC, a positive impact on survival was suggested when radiotherapy was added to the TKI [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.